AgomAb Therapeutics N.V. American Depositary Shares Long Term Debt

The latest long-term debt for AGMB is $910K as of June 2026. Investors often review this figure alongside AgomAb Therapeutics N.V. American Depositary Shares's historical trend and sector peers before judging valuation or financial health.

A long-term debt figure of $910K for AGMB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AGMB's long-term debt ($910K), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack AgomAb Therapeutics N.V. American Depositary Shares's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.